Business Daily Media

Men's Weekly

.

CK Life Sciences Files Patent Applications for Circular mRNA TROP2 Cancer Vaccine

Breast Cancer Animal Studies Show Unprecedented Anti-Cancer Efficacy of 100% Tumor Growth Inhibition

HONG KONG SAR - Media OutReach Newswire - 11 April 2025 - CK Life Sciences Int'l., (Holdings) Inc.

("CK Life Sciences"), a leader in cancer vaccine development, announces the latest progress in its pharmaceutical R&D, namely the filing of an Original Grant Patent application in Hong Kong and a provisional patent application in the United States for novel cancer vaccines targeting Trophoblast Cell Surface Antigen 2 ("TROP2").

TROP2 is a cell surface glycoprotein that is overexpressed in a wide range of cancers, including breast, lung, pancreatic, and colorectal cancers. This protein plays a critical role in cell proliferation, migration, and invasion, and its overexpression is frequently linked to aggressive tumor behavior and poor clinical outcomes. Given its high expression in cancer cells and minimal presence in normal tissues, TROP2 has emerged as a promising therapeutic target in oncology.

TROP2-positive triple-negative breast cancer animal study demonstrated 100% tumor growth inhibition

TROP2 cancer vaccines covered by the patent application include innovative circular mRNA (circRNA) and fusion protein vaccine constructs that can induce robust T cell immune responses and have demonstrated impressive tumor growth inhibition in preclinical studies of triple-negative breast cancer and colorectal cancer. The results of animal studies involving triple-negative breast cancer ("TNBC") have been encouraging, with mouse models showing 100% tumor growth inhibition after receiving the TROP2 cancer vaccine. Overall, 100% inhibition of tumor growth was achieved in four of the five studies when mice were treated with a TROP2 vaccine candidate, while the remaining study demonstrated approximately 80% tumor growth inhibition.

Triple-negative breast cancer disproportionately prevalent and aggressive among Asian women

The results of animal studies of the TROP2 cancer vaccines are of particular relevance to the Asian region. Breast cancer rates in Asia are rising sharply, with younger women widely affected. In particular, TNBC shows both higher prevalence and more aggressive behavior in Asian populations compared to Western counterparts. Additionally, TNBC has fewer treatment options and demonstrates significantly higher rates of metastasis and recurrence than other breast cancer subtypes.

Unprecedented anti-cancer efficacy

"TROP2 is an exciting therapeutic target and preclinical studies of our cancer vaccine in triple-negative breast cancer exhibited 100% inhibition of tumor growth, demonstrating unprecedented anti-cancer efficacy. We look forward to advancing our TROP2 cancer vaccine expeditiously into clinical trials to benefit patients and believe it holds significant potential in preventing cancer recurrence," said Dr. Melvin Toh, Chief Scientific Officer at CK Life Sciences.

Data on the TROP2 cancer vaccines will be presented at upcoming cancer conferences. In recent years, CK Life Sciences has showcased its growing early-stage cancer vaccine pipeline through preclinical data presentations at leading oncology conferences, alongside the filing of multiple patents. Developed in its Hong Kong-based R&D laboratories, these innovative vaccines target a broad spectrum of tumor antigens, immune checkpoint proteins, and other key components within the tumor-immune microenvironment.




Hashtag: #CKLifeSciences #CancerVaccines #R&D #BreastCancer #PatentApplication #Pharmaceutical

The issuer is solely responsible for the content of this announcement.

About CK Life Sciences

CK Life Sciences Int'l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission of improving the quality of life, CK Life Sciences is engaged in healthcare research and development, with operating businesses that enable its R&D sustainability. Regarding pharmaceutical research and development, CK Life Sciences' operations are focused on conducting research and development into cancer vaccines and pain management solutions. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit .

News from Asia

Lee Kuan Yew School of Public Policy Releases Strategic Roadmap for ASEAN's 5G-AI Transformation

New Research Reveals US$130 Billion Economic Opportunity and Outlines Policy Framework to Accelerate Regional Digital Leadership by 2030SINGAPORE - Media OutReach Newswire - 22 July 2025 - The Le...

DFI Retail Group Holdings Limited Half-Year Results For The Six Months Ended 30 June 2025 And Announcement Of Special Dividend

Highlights 39% underlying earnings growth Increased contributions from associates, Health & Beauty and Food Health & Beauty delivered strong like-for-like (LFL...

HeyMax Acquires Hong Kong’s krip to Accelerate Regional Expansion into Loyalty and Rewards Market

HeyMax’s first acquisition fast-tracks its regional expansion, bringing over 6,000 credit card deals offered by over 3,000 merchants, and personalized loyalty experiences to consumers in Hong Kong ...

CUHK Faculty of Engineering: Advancing Innovation Through Research Excellence and Global Collaboration

HONG KONG SAR - Media OutReach Newswire - 23 July 2025 - The Faculty of Engineering at The Chinese University of Hong Kong (CUHK) continues to strengthen its position in global engineering educat...

Adecco Singapore Marks 40 Years of Enabling Talent and Business Growth

SINGAPORE - Media OutReach Newswire - 23 July 2025 - Adecco Singapore has officially commemorated its 40th anniversary with a stakeholder event held at the National Gallery Singapore. The occasion...

Samsung’s Solve for Tomorrow 2025 Youth Innovation Competition is Now On

SINGAPORE - Media OutReach Newswire - 23 July 2025 - Samsung Solve for Tomorrow 2025, the highly-anticipated youth innovation competition, is back for its ninth edition in Singapore! As the natio...

Jollibee Group Evolves its Corporate Brand to Help Power Global Growth

Brand update brings to life its global purpose and positioning as a unified group of brandsMANILA, PHILIPPINES - Media OutReach Newswire - 23 July 2025 - The Jollibee Group, one of the world's fas...

AECOM to enhance mobility across the Greater Bay Area by delivering the Hong Kong Section of Hong Kong–Shenzhen Western Rail Link (Hung Shui Kiu-Qianhai)

HONG KONG SAR - Media OutReach Newswire - 23 July 2025 - AECOM, the trusted global infrastructure leader, today announced that its joint venture with AtkinsRéalis has been awarded the consultancy ...

OCBC Hong Kong Unveils New Brand Campaign

Connected to “As One Group, OCBC Enables Aspiration All Across ASEAN and Greater China” Demonstrating the Unwavering Commitment in Realising Customer’s Aspirations HONG KONG SAR - Media...

X.me Foundation Empowers Global Expansion of the X.me Social Media Platform

SINGAPORE - Media OutReach Newswire - 23 July 2025 - X.me (https://x.me) is a social media platform where users can freely express themselves, share content, engage, and interact while earnin...

Baby boomers are driving development feasibility leading to larger apartments

As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...

Hays launches FY25/26 Salary Guide: ‘Salary Paradox’ deepens as pay rises fail Australians

Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...

Australian Businesses Still Stuck in the AI Hype Cycle

Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

Sell by LayBy